Community Practice Connections™: Integrating CAR T-Cell Therapy for the Treatment of Lymphoid Malignancies: What the Community Oncologist Needs to Know

Community Practice Connections™: Integrating CAR T-Cell Therapy for the Treatment of Lymphoid Malignancies: What the Community Oncologist Needs to Know is organized by Physicians' Education Resource, LLC (PER).

Release Date: July 31, 2019
Expiration Date: July 31, 2020

Target Audience:
This educational activity is directed toward community oncologists and hematologists who treat patients with lymphoid malignancies. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of lymphoid malignancies will also be invited to participate.

Accreditation/Credit Designation:
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.

Activity Overview:
Community Practice Connections™: Integrating CAR T-Cell Therapy for the Treatment of Lymphoid Malignancies: What the Community Oncologist Needs To Know provides case-based discussion of clinical data on the use of chimeric antigen receptor (CAR) T cells in patients with lymphoid malignancies, with a focus on acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). Interactive clinical vignettes are followed by short video interviews with leading experts in the management of patients with ALL and DLBCL. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting by healthcare professionals utilizing CAR T-cell therapy for patients with lymphoid malignancies.

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Recognize the unique mechanism of CAR T-cell action and the nuances of the manufacture of CAR T-cell therapy
• Evaluate clinical trial data in the context of CAR T-cell therapy and its place in evolving hematologic malignancy treatment paradigms
• Explain pathways for the use of CAR T cells, including identification of eligible patients, process of referral to the treatment centers, and the importance of posttreatment follow-up
• Determine the potential CAR T-cell treatment-related toxicities and best practices for adverse event detection, grading, monitoring, management, and mitigation.